World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
87
Citations
29781
World Ranking
13583
National Ranking
559

Overview

Yves Fradet is affiliated with Université Laval in Canada and has a research portfolio comprising extensive work in medicine and biochemistry, genetics, and molecular biology. Their studies focus primarily on surgery, oncology, pulmonary and respiratory medicine, molecular biology, and cancer research.

The researcher has contributed notably to topics such as bladder and urothelial cancer treatments, cancer immunotherapy and biomarkers, urinary and genital oncology studies, prostate cancer treatment and research, cancer, lipids, and metabolism, prostate cancer diagnosis and treatment, and metabolomics and mass spectrometry studies.

Fradet's work has appeared frequently in prominent scientific journals, including the Journal of Clinical Oncology, Annals of Oncology, Canadian Urological Association Journal, Cancer Immunology Research, and The Journal of Urology. These venues are the primary platforms for their contributions to the academic community.

Their research collaborations involve frequent co-authors, notably Alain Bergeron, Vincent Fradet, Louis Lacombe, Paul Toren, and Blanca Homet Moreno, each contributing across numerous joint publications.

Among the notable recent papers affiliated with Fradet's work are:

  • Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial, 2021, The Lancet Oncology
  • Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial, 2020, The Lancet Oncology
  • A Natural Polyphenol Exerts Antitumor Activity and Circumvents Anti-PD-1 Resistance through Effects on the Gut Microbiota, 2022, Cancer Discovery
  • Cardiovascular Risk in Men with Prostate Cancer: Insights from the RADICAL PC Study, 2020, The Journal of Urology
  • Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up, 2022, Annals of Oncology

Best Publications

  • Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

    Joaquim Bellmunt;Ronald De Wit;David J. Vaughn;Yves Fradet

  • PCA3: A Molecular Urine Assay for Predicting Prostate Biopsy Outcome

    Ina L. Deras;Sheila M.J. Aubin;Amy Blase;John R. Day

  • Genomic hallmarks of localized, non-indolent prostate cancer

    Michael Fraser;Veronica Y. Sabelnykova;Takafumi N. Yamaguchi;Lawrence E. Heisler

  • Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers

    Vinata B. Lokeshwar;Tomonori Habuchi;H. Barton Grossman;William M. Murphy

  • PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression.

    Brant A. Inman;Thomas J. Sebo;Xavier Frigola;Haidong Dong

  • Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.

    Thomas Powles;Thomas Powles;Tibor Csőszi;Mustafa Özgüroğlu;Nobuaki Matsubara

  • Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data

    Maximilian Burger;H. Barton Grossman;Michael Droller;Joerg Schmidbauer

  • Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

    Thomas Powles;Michiel S van der Heijden;Daniel Castellano;Matthew D Galsky

  • Urine TMPRSS2:ERG Fusion Transcript Stratifies Prostate Cancer Risk in Men with Elevated Serum PSA

    Scott A. Tomlins;Sheila M. J. Aubin;Javed Siddiqui;Robert J. Lonigro

  • Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group.

    M E Gleave;M Elhilali;Y Fradet;I Davis

  • A Comparison of Hexaminolevulinate Fluorescence Cystoscopy and White Light Cystoscopy for the Detection of Carcinoma In Situ in Patients With Bladder Cancer: A Phase III, Multicenter Study

    Yves Fradet;H. Barton Grossman;Leonard Gomella;Seth Lerner

  • A Phase III, Multicenter Comparison of Hexaminolevulinate Fluorescence Cystoscopy and White Light Cystoscopy for the Detection of Superficial Papillary Lesions in Patients With Bladder Cancer

    H. Barton Grossman;Leonard Gomella;Yves Fradet;Alvaro Morales

  • Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

    Y Fradet;J Bellmunt;D J Vaughn;J L Lee

  • Urinary diversion after radical cystectomy for bladder cancer: Options, patient selection, and outcomes

    Richard K. Lee;Hassan Abol-Enein;Walter Artibani;Bernard Bochner

  • Widespread and Functional RNA Circularization in Localized Prostate Cancer

    Sujun Chen;Sujun Chen;Sujun Chen;Vincent Huang;Xin Xu;Julie Livingstone

  • Cell surface antigens of human bladder cancer defined by mouse monoclonal antibodies

    Yves Fradet;Carlos Cordon-Cardo;Timothy Thomson;Mary E. Daly

  • Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302)

    Dana E. Rathkopf;Matthew R. Smith;Johann S. De Bono;Christopher J. Logothetis

  • Hexaminolevulinate Guided Fluorescence Cystoscopy Reduces Recurrence in Patients With Nonmuscle Invasive Bladder Cancer

    Arnulf Stenzl;Maximilian Burger;Yves Fradet;Lance A. Mynderse

  • uPM3, a new molecular urine test for the detection of prostate cancer.

    Yves Fradet;Fred Saad;Armen Aprikian;Jean Dessureault

  • Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort.

    Hans Martin Fritsche;Maximilian Burger;Robert S. Svatek;Claudio Jeldres

Frequent Co-Authors

Wassim Kassouf
Wassim Kassouf McGill University
Shahrokh F. Shariat
Shahrokh F. Shariat Medical University of Vienna
Yair Lotan
Yair Lotan The University of Texas Southwestern Medical Center
Pierre I. Karakiewicz
Pierre I. Karakiewicz University of Montreal
Fred Saad
Fred Saad University of Montreal
Giacomo Novara
Giacomo Novara University of Padua
Seth P. Lerner
Seth P. Lerner Baylor College of Medicine
Patrick J. Bastian
Patrick J. Bastian Ludwig-Maximilians-Universität München
Colin P. Dinney
Colin P. Dinney The University of Texas MD Anderson Cancer Center
Vincenzo Ficarra
Vincenzo Ficarra University of Messina

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in healthcare careers but seeking flexible study options, online degrees offer valuable pathways. Many choose programs like medical coding certification cost programs, which can provide a quick entry into medical administrative roles. The investment is often significantly lower than traditional, on-campus degrees.

Nursing is another popular online study area. If you’re considering becoming a nurse practitioner, you can explore cheapest online np programs to help minimize student debt while qualifying for advanced clinical positions. Curious about general nursing programs? Find details such as how much is online nursing school to compare expenses across accredited options.

For experienced nurses seeking leadership or educator roles, doctorate in nursing education online programs provide a flexible path toward the highest credentials in the field. Overall, online healthcare education can greatly expand access to rewarding medical careers while helping students manage costs.

Best Scientists Citing Yves Fradet

Trending Scientists